Business Context and Reporting Period
Company: Cardo Medical, Inc. (formerly clickNsettle.com, Inc. following a reverse takeover in August 2008; also referred to as Biocardia in metadata).
Reporting Period: Quarterly period ended March 31, 2009.
Business Overview: An early-stage orthopedic medical device company specializing in reconstructive joint devices (knee, hip) and spinal surgical devices. The company operates two reportable segments: Reconstructive Division and Spine Division. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $432,000 | $305,000 |
| Gross Profit | $350,000 | $260,000 |
| Gross Margin | 81.0% | 85.2% |
| Net Loss | $(1,224,000) | $(199,000) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.00) |
| Cash and Equivalents (End of Period) | $1,680,000 | $524,000 |
| Net Cash Used in Operating Activities | $(983,000) | $(277,000) |
| Total Assets | $10,445,000 | $11,474,000 |
| Total Liabilities | $941,000 | $777,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 41.6% to $432,000, driven primarily by wider acceptance of the knee product ($110,000 increase) and licensed products ($68,000).
- Expense Surge: Selling, general, and administrative (SG&A) expenses increased 277.4% to $1,536,000. This was due to increased payroll ($610,000) for new hires and higher amortization/depreciation ($213,000) from new instrumentation and acquisitions.
- R&D Reduction: Research and development expenses decreased 65.4% to $46,000 due to reduced research on knee and licensed products.
- Profitability: The net loss widened significantly by 515.1% to $1,224,000, primarily driven by the spike in SG&A expenses.
- Cash Flow: Net cash used in operating activities increased to $983,000 from $277,000. Investing activities consumed $432,000, primarily for purchasing instrumentation.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management explicitly states that as of May 15, 2009, cash on hand ($845,000) is insufficient to meet working capital needs for the next 12 months. The filing includes a "going concern" uncertainty warning. The company requires additional capital via debt or equity financing to continue operations.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2009. Material weaknesses were identified regarding adequate qualified staff and methods for reporting unusual transactions (specifically the reverse merger).
- Segment Performance: The Reconstructive Division generated a net income of $335,000, while the Corporate segment incurred a loss of $1,574,000, absorbing the majority of the company's operating losses.
- Risks: Key risks include the inability to secure financing, dependence on third-party payors for reimbursement, reliance on single-source manufacturers, and the need for FDA clearances for product modifications.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure the necessary debt or equity financing to survive the next 12 months, given the explicit liquidity warning.
- Internal Controls: Monitor progress on remediating the material weaknesses in internal controls over financial reporting.
- Customer Concentration: Note that four customers accounted for 74.2% of sales in Q1 2009, creating significant concentration risk.
- Expense Trajectory: Assess whether the 277% increase in SG&A expenses is sustainable or if cost-cutting measures will be required if financing is delayed.
- Stock Dilution: Evaluate the potential for significant dilution if the company raises capital through equity offerings, as 203 million shares are currently outstanding.